EUCTR2008-005546-23-IT进行中（未招募）1 期
Insulin Resistance Intervention after Stroke (IRIS) Trial - ND
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 3,876
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •a. Ages 40 years or greater at the time of randomization. b. Ischemic stroke or TIA no less than 14 days and no more than 6 months before randomization c. Documentation of insulin resistance as defined by a value over 3.0 on the Homeostasis Model Assessment of insulin sensitivity (HOMA). d. Both ability and willingness to provide informed
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Permanent Exclusions a. Severely disabling stroke as indicated by an inability to participate in scheduled follow-up activities. b. Persons whose ischemic stroke or TIA was related to structural cardiac lesion, significant head trauma, proximal arterial dissection or medical instrumentation. c. Diabetes mellitus as defined by recent use of medication for diabetes as an out-patient (*see note below) or two fasting plasma blood sugars > 126 mg/dL. d. HgbA1c > 7.0%. e. Irreversible medical conditions likely to affect short-term survival or ability to participate in the study protocol. These include: Cancer or other chronic disease with poor prognosis (predicted survival of less than four years). Severe neurologic or psychiatric disease that would complicate the evaluation of study outcomes (e.g., dementia or schizophrenia). f. History of intolerance to any thiazolidinedione. g. Pregnancy or desire to become pregnant. h. Oral contraceptive use. i. Ongoing use of oral corticosteroids. j. History of heart failure k. Active liver disease as defined by known liver disease accompanied by cirrhosis, significant cholestasis, portal hypertension, hepatic encephalopathy, hepatic synthetic dysfunction, or expected significant loss of liver function over the course of the study. l. History of bladder cancer. m. Current participation in a conflicting clinical trial. A conflicting clinical trial is defined as a trial with any of following: Intervention that is known to affect the incidence of stroke or myocardial infarction. Intervention that is an experimental drug. Outcome that includes stroke or myocardial infarction. Exclusion for participation in another trial. Temporary Exclusions Persons with temporary exclusions may be enrolled as soon as the exclusion has resolved. a. ALT >2.5 times the upper limit of normal. b. Hemoglobin <8.5 g/dl. c. Moderate or severe pitting edema of the feet or legs (IRIS grade 3 or 4). d. Carotid surgery or carotid stenting procedure scheduled (delay randomization until 2 weeks following procedure).
研究者
相似试验
进行中（未招募）
不适用
Treating Insulin Resistance in patient after Stroke for prevention of stroke and myocardial infarction after ischemic stroke and transient ischemic attackEUCTR2008-005546-23-DEYale University School of Medicine3,936
进行中（未招募）
1 期
The Insulin Resistance Intervention after Stroke Trial A randomized, placebo-controlled trial of pioglitazone, compared with placebo, for prevention of stroke and myocardial infarction after ischemic stroke and transient ischemic attack - The Insulin Resistance Intervention after Stroke (IRIS) trialInsulin resistance in patients who have had a stroke or transient ischaemic attackEUCTR2008-005546-23-GBYale University School of Medicine3,876
已完成
不适用
Juntendo the Stroke Prevention study in Insulin Resistance and Impaired glucose Tolerance (J-SPIRIT study)symptomatic ischemic stroke or transient ischemic attacak (TIA)JPRN-UMIN000013499Department of Neurology, Juntendo University School of Medicine200
已完成
3 期
Insulin Resistance Intervention After Stroke TrialStrokeDiabetesMyocardial InfarctionNCT00091949Yale University3,876
尚未招募
不适用
Insulin Resistance in Egyptian Patients With Multiple SclerosisMultiple SclerosisInsulin ResistanceNCT06017726Assiut University100